BD and Fujirebio Diagnostics Sign Worldwide Agreement to Develop Biomarker Assays to Improve Cancer Detection and Management

BD (Becton, Dickinson and Company; NYSE: BDX) and Fujirebio Diagnostics, Inc., announced today the signing of a worldwide development and supply agreement for oncology diagnostic assays.

Malvern, PA, USA - May 4th, 2009 - BD (Becton, Dickinson and Company; NYSE: BDX) and Fujirebio Diagnostics, Inc., announced today the signing of a worldwide development and supply agreement for oncology diagnostic assays.

> View the complete press release (PDF)